Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)

Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left untreated. The treatment landscape for DR and DME is evolving rapidly, with established anti-VEGF therapies such as Eylea and off-label Avastin remaining central to management. Additionally, the sustained-release corticosteroid implants Ozurdex and Iluvien provide alternative options. Since 2022, the market has seen increased competition with the launch of Vabysmo, Eylea HD / Eylea 8 mg, and biosimilars of Eylea. The anticipated approvals of Regenxbio / AbbVie’s sura-vec SCS and 4DMT / Otsuka’s 4D-150—two innovative gene therapies—and EyePoint’s Duravyu, Ocular Therapeutix’s Axpaxli, and Ashvattha’s migaldendranib—three novel TKIs—represent a breakthrough in the treatment of retinal diseases and are likely to shift the current treatment paradigm and could transform the treatment of DR and DME patients in the future. 

Questions answered

• How large are the treatable DR and DME populations, and how will diagnosis and drug-treatment rates change over time?
• What key differences do KOLs perceive between current IVT therapies? How is the use of these drugs expected to change over the next 10 years?
• How will DR and DME treatment algorithms change as innovative products like gene therapies and long-acting TKIs launch?
• How will market dynamics be impacted by the launch of biosimilars of Eylea?

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.